{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T16:12:48Z","timestamp":1785168768714,"version":"3.55.0"},"reference-count":49,"publisher":"American Medical Association (AMA)","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Nonalcoholic fatty liver disease (NAFLD) is a cardiovascular risk factor, but whether sodium-glucose cotransporter-2 inhibitors (SGLT-2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) are associated with reduced cardiovascular risk in patients with type 2 diabetes (T2D) and concomitant NAFLD remains uncertain.<\/jats:p><\/jats:sec>Objective<\/jats:title>To investigate the outcomes of SGLT-2i and GLP-1RA therapy among patients with T2D varied by the presence or absence of NAFLD.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This retrospective, population-based, nationwide cohort study used an active-comparator new-user design. Two distinct new-user active-comparator cohorts of patients aged 40 years and older who initiated SGLT-2i or GLP-1RA were propensity score matched to patients who initiated dipeptidyl peptidase-4 inhibitors (DPP-4i). The study was conducted in South Korea from January 2013 to December 2020, and data analysis was conducted from October 2022 to March 2023.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>The main outcomes were (1) major adverse cardiovascular events (MACE), a composite end point of hospitalization for myocardial infarction, hospitalization for stroke, and cardiovascular death, and (2) hospitalization for heart failure (HHF). Cox proportional hazards models were used to estimate hazard ratios (HRs). The Wald test was applied to assess heterogeneity by NAFLD.<\/jats:p><\/jats:sec>Results<\/jats:title>After 1:1 propensity score matching, 140\u202f438 patients were retrieved in the first cohort (SGLT-2i vs DPP-4i; mean [SD] age, 57.5 [10.3] years; 79\u202f633 [56.7%] male) and 34\u202f886 patients were identified in the second cohort (GLP-1RA vs DPP-4i; mean [SD] age, 59.5 [10.5] years; 17\u202f894 [51.3%] male). Compared with DPP-4i, SGLT-2i therapy was associated with a lower risk of MACE (HR, 0.78 [95% CI, 0.71-0.85]) and HHF (HR, 0.62 [95% CI, 0.48-0.81]). GLP-1RA therapy was associated with a decreased risk of MACE (HR, 0.49 [95% CI, 0.39-0.62]) but had statistically nonsignificant findings regarding HHF (HR, 0.64 [95% CI, 0.39-1.07]). Stratified analysis by NAFLD status yielded consistent results for SGLT-2i (MACE with NAFLD: HR, 0.73 [95% CI, 0.62-0.86]; without NAFLD: HR, 0.81 [95% CI, 0.72-0.91]; HHF with NAFLD: HR, 0.76 [95% CI, 0.49-1.17]; without NAFLD: HR, 0.56 [95% CI, 0.40-0.78]) and for GLP-1RA (MACE with NAFLD: HR, 0.49 [95% CI, 0.32-0.77]; without NAFLD: HR, 0.49 [95% CI, 0.37-0.65]; HHF with NAFLD: HR, 0.82 [95% CI, 0.38-1.76]; without NAFLD: HR, 0.54 [95% CI, 0.27-1.06]).<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this population-based cohort study, SGLT-2i therapy was associated with a decreased risk of MACE and HHF, while GLP-1RA therapy was associated with a decreased risk of MACE among patients with T2D, irrespective of baseline NAFLD status.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2023.49856","type":"journal-article","created":{"date-parts":[[2023,12,28]],"date-time":"2023-12-28T16:32:22Z","timestamp":1703781142000},"page":"e2349856","source":"Crossref","is-referenced-by-count":22,"title":["Outcomes of SGLT-2i and GLP-1RA Therapy Among Patients With Type 2 Diabetes and Varying NAFLD Status"],"prefix":"10.1001","volume":"6","author":[{"given":"Sungho","family":"Bea","sequence":"first","affiliation":[{"name":"School of Pharmacy, Sungkyunkwan University, Suwon, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han Eol","family":"Jeong","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Sungkyunkwan University, Suwon, South Korea"},{"name":"Department of Biohealth Regulatory Science, Sungkyunkwan University, Suwon, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristian B.","family":"Filion","sequence":"additional","affiliation":[{"name":"Departments of Medicine and of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Quebec, Canada"},{"name":"Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oriana HY","family":"Yu","sequence":"additional","affiliation":[{"name":"Centre for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, Montreal, Quebec, Canada"},{"name":"Division of Endocrinology and Metabolism, Jewish General Hospital, McGill University, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Min","family":"Cho","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea"},{"name":"Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bon Hyang","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoosoo","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Biohealth Regulatory Science, Sungkyunkwan University, Suwon, South Korea"},{"name":"Center for Cohort Studies, Total Healthcare Center, Kangbuk Samsung Hospital Sungkyunkwan University School of Medicine, Seoul, South Korea"},{"name":"Department of Occupational and Environmental Medicine, Kangbuk Samsung Hospital Sungkyunkwan University School of Medicine, Seoul, South Korea"},{"name":"Department of Clinical Research Design & Evaluation, Samsung Advanced Institute for Health Sciences & Technology, Sungkyunkwan University, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher D.","family":"Byrne","sequence":"additional","affiliation":[{"name":"Nutrition and Metabolism, Faculty of Medicine, University of Southampton, Southampton, United Kingdom"},{"name":"National Institute for Health and Care Research, Southampton Biomedical Research Centre, University Hospital Southampton, Southampton, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju-Young","family":"Shin","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Sungkyunkwan University, Suwon, South Korea"},{"name":"Department of Biohealth Regulatory Science, Sungkyunkwan University, Suwon, South Korea"},{"name":"Department of Clinical Research Design & Evaluation, Samsung Advanced Institute for Health Sciences & Technology, Sungkyunkwan University, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2023,12,28]]},"reference":[{"issue":"1","key":"zoi231449r1","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1016\/j.jhep.2014.12.012","article-title":"NAFLD: a multisystem disease.","volume":"62","author":"Byrne","year":"2015","journal-title":"J Hepatol"},{"issue":"7","key":"zoi231449r2","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/S2468-1253(21)00020-0","article-title":"Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach.","volume":"6","author":"Targher","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"zoi231449r3","doi-asserted-by":"publisher","first-page":"372","DOI":"10.2337\/dc17-1902","article-title":"Nonalcoholic fatty liver disease and risk of incident type 2 diabetes: a meta-analysis.","volume":"41","author":"Mantovani","year":"2018","journal-title":"Diabetes Care"},{"issue":"5","key":"zoi231449r4","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1136\/gutjnl-2020-322572","article-title":"Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals.","volume":"70","author":"Mantovani","year":"2021","journal-title":"Gut"},{"issue":"9","key":"zoi231449r5","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1038\/s41575-021-00448-y","article-title":"The complex link between NAFLD and type 2 diabetes mellitus\u2014mechanisms and treatments.","volume":"18","author":"Targher","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"11","key":"zoi231449r6","doi-asserted-by":"publisher","first-page":"2389","DOI":"10.1038\/ajg.2010.275","article-title":"Impact of nonalcoholic fatty liver disease on insulin resistance in relation to HbA1c levels in nondiabetic subjects.","volume":"105","author":"Bae","year":"2010","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"zoi231449r7","doi-asserted-by":"publisher","first-page":"727","DOI":"10.2337\/dc10-1991","article-title":"Combined effect of nonalcoholic fatty liver disease and impaired fasting glucose on the development of type 2 diabetes: a 4-year retrospective longitudinal study.","volume":"34","author":"Bae","year":"2011","journal-title":"Diabetes Care"},{"issue":"4","key":"zoi231449r8","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/S2213-8587(22)00003-1","article-title":"A global view of the interplay between non-alcoholic fatty liver disease and diabetes.","volume":"10","author":"Stefan","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"zoi231449r9","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease\u2014meta-analytic assessment of prevalence, incidence, and outcomes.","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"issue":"10193","key":"zoi231449r10","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"issue":"15","key":"zoi231449r11","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease.","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"issue":"19","key":"zoi231449r12","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes.","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"4","key":"zoi231449r13","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes.","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"7","key":"zoi231449r14","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes.","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"issue":"8","key":"zoi231449r15","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1161\/CIRCULATIONAHA.121.055459","article-title":"Effect of the glucagon-like peptide-1 receptor agonists semaglutide and liraglutide on kidney outcomes in patients with type 2 diabetes: pooled analysis of SUSTAIN 6 and LEADER.","volume":"145","author":"Shaman","year":"2022","journal-title":"Circulation"},{"issue":"22","key":"zoi231449r16","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes.","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"zoi231449r17","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes.","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"zoi231449r18","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2023.01.031","article-title":"Sodium-glucose cotransporter-2 inhibitors and risk of hepatocellular carcinoma among patients with type 2 diabetes.","author":"Bea","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"zoi231449r19","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1136\/gutjnl-2022-327504","article-title":"Hepatic events associated with sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes: a nationwide cohort study.","volume":"72","author":"Bea","year":"2023","journal-title":"Gut"},{"issue":"2","key":"zoi231449r20","doi-asserted-by":"publisher","first-page":"298","DOI":"10.2337\/dc19-0641","article-title":"Empagliflozin effectively lowers liver fat content in well-controlled type 2 diabetes: a randomized, double-blind, phase 4, placebo-controlled trial.","volume":"43","author":"Kahl","year":"2020","journal-title":"Diabetes Care"},{"issue":"8","key":"zoi231449r21","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.2337\/dc18-0165","article-title":"Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT Trial).","volume":"41","author":"Kuchay","year":"2018","journal-title":"Diabetes Care"},{"issue":"12","key":"zoi231449r22","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis.","volume":"384","author":"Newsome","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"zoi231449r23","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1016\/j.cgh.2021.07.010","article-title":"Glucagon-like peptide-1 receptor agonists and hepatic decompensation events in patients with cirrhosis and diabetes.","volume":"20","author":"Simon","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"zoi231449r24","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cmet.2017.04.011","article-title":"Sodium-glucose co-transporters and their inhibition: clinical physiology.","volume":"26","author":"Ferrannini","year":"2017","journal-title":"Cell Metab"},{"key":"zoi231449r25","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/dom.2010.12.issue-s2","article-title":"Hepatic steatosis: a role for de novo lipogenesis and the transcription factor SREBP-1c.","volume":"12","author":"Ferr\u00e9","year":"2010","journal-title":"Diabetes Obes Metab"},{"issue":"16","key":"zoi231449r26","doi-asserted-by":"publisher","first-page":"9116","DOI":"10.1073\/pnas.161284298","article-title":"A glucose-responsive transcription factor that regulates carbohydrate metabolism in the liver.","volume":"98","author":"Yamashita","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"zoi231449r27","doi-asserted-by":"publisher","first-page":"649","DOI":"10.3389\/fendo.2018.00649","article-title":"Future perspectives on GLP-1 receptor agonists and GLP-1\/glucagon receptor co-agonists in the treatment of NAFLD.","volume":"9","author":"Seghieri","year":"2018","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"11","key":"zoi231449r28","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/S2468-1253(21)00308-3","article-title":"Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysis.","volume":"6","author":"Mantovani","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"24","key":"zoi231449r29","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1001\/jama.2022.21383","article-title":"Target trial emulation: a framework for causal inference from observational data.","volume":"328","author":"Hern\u00e1n","year":"2022","journal-title":"JAMA"},{"issue":"3","key":"zoi231449r30","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1093\/ije\/dyw253","article-title":"Data resource profile: the National Health Information Database of the National Health Insurance Service in South Korea.","volume":"46","author":"Cheol Seong","year":"2017","journal-title":"Int J Epidemiol"},{"issue":"2","key":"zoi231449r31","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.0262","article-title":"Analysis of severe hypoglycemia among adults with type 2 diabetes and nonalcoholic fatty liver disease.","volume":"5","author":"Lee","year":"2022","journal-title":"JAMA Netw Open"},{"key":"zoi231449r32","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1471-230X-6-33","article-title":"The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population.","volume":"6","author":"Bedogni","year":"2006","journal-title":"BMC Gastroenterol"},{"issue":"9","key":"zoi231449r33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0107584","article-title":"Non-laboratory-based self-assessment screening score for non-alcoholic fatty liver disease: development, validation and comparison with other scores.","volume":"9","author":"Lee","year":"2014","journal-title":"PLoS One"},{"key":"zoi231449r34","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2022.110191","article-title":"The association between changes in hepatic steatosis and hepatic fibrosis with cardiovascular outcomes and mortality in patients with new-onset type 2 diabetes: a nationwide cohort study.","volume":"194","author":"Park","year":"2022","journal-title":"Diabetes Res Clin Pract"},{"issue":"1","key":"zoi231449r35","doi-asserted-by":"publisher","first-page":"6","DOI":"10.2337\/dc17-1223","article-title":"Lower risk of death with SGLT2 Inhibitors in observational studies: real or bias?","volume":"41","author":"Suissa","year":"2018","journal-title":"Diabetes Care"},{"issue":"2","key":"zoi231449r36","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.jhep.2016.04.021","article-title":"Sitagliptin vs. placebo for non-alcoholic fatty liver disease: a randomized controlled trial.","volume":"65","author":"Cui","year":"2016","journal-title":"J Hepatol"},{"issue":"991","key":"zoi231449r37","doi-asserted-by":"publisher","first-page":"n991","DOI":"10.1136\/bmj.n991","article-title":"Treatment timing and the effects of rhythm control strategy in patients with atrial fibrillation: nationwide cohort study.","volume":"373","author":"Kim","year":"2021","journal-title":"BMJ"},{"issue":"25","key":"zoi231449r38","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1002\/sim.v28:25","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples.","volume":"28","author":"Austin","year":"2009","journal-title":"Stat Med"},{"issue":"7","key":"zoi231449r39","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.dld.2009.08.002","article-title":"Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease.","volume":"42","author":"Lee","year":"2010","journal-title":"Dig Liver Dis"},{"issue":"446","key":"zoi231449r40","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk.","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"key":"zoi231449r41","doi-asserted-by":"publisher","first-page":"l5657","DOI":"10.1136\/bmj.l5657","article-title":"Alternative approaches for confounding adjustment in observational studies using weighting based on the propensity score: a primer for practitioners.","volume":"367","author":"Desai","year":"2019","journal-title":"BMJ"},{"key":"zoi231449r42","doi-asserted-by":"publisher","first-page":"m3342","DOI":"10.1136\/bmj.m3342","article-title":"Sodium glucose cotransporter 2 inhibitors and risk of major adverse cardiovascular events: multi-database retrospective cohort study.","volume":"370","author":"Filion","year":"2020","journal-title":"BMJ"},{"key":"zoi231449r43","doi-asserted-by":"publisher","first-page":"k119","DOI":"10.1136\/bmj.k119","article-title":"Cardiovascular outcomes associated with canagliflozin versus other non-gliflozin antidiabetic drugs: population based cohort study.","volume":"360","author":"Patorno","year":"2018","journal-title":"BMJ"},{"issue":"13","key":"zoi231449r44","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes.","volume":"377","author":"Holman","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"zoi231449r45","first-page":"457","article-title":"Impairment of the left ventricular systolic and diastolic function in patients with non-alcoholic fatty liver disease.","volume":"17","author":"Fotbolcu","year":"2010","journal-title":"Cardiol J"},{"issue":"8","key":"zoi231449r46","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/oby.v25.8","article-title":"Nonalcoholic steatohepatitis is associated with cardiac remodeling and dysfunction.","volume":"25","author":"Simon","year":"2017","journal-title":"Obesity (Silver Spring)"},{"issue":"3","key":"zoi231449r47","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1002\/hep.27869","article-title":"Association of nonalcoholic fatty liver disease with subclinical myocardial remodeling and dysfunction: a population-based study.","volume":"62","author":"VanWagner","year":"2015","journal-title":"Hepatology"},{"issue":"11","key":"zoi231449r48","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/j.jacbts.2021.07.010","article-title":"Relationship of nonalcoholic fatty liver disease and heart failure with preserved ejection fraction.","volume":"6","author":"Salah","year":"2021","journal-title":"JACC Basic Transl Sci"},{"issue":"10319","key":"zoi231449r49","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S0140-6736(21)01701-3","article-title":"The EASL-Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality.","volume":"399","author":"Karlsen","year":"2022","journal-title":"Lancet"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2813411\/bea_2023_oi_231449_1702931683.09297.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,28]],"date-time":"2023-12-28T16:32:27Z","timestamp":1703781147000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2813411"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,28]]},"references-count":49,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.49856","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,28]]}}}